港股異動 | 中國飛鶴(6186.HK)漲超5% 獲納入MSCI全中國指數成份股
格隆匯5月13日丨中國飛鶴(6186.HK)現報15.18港元,漲5.12%,暫成交1.7億港元,最新總市值1356億港元。指數編制公司MSCI明晟公佈半年度指數成分股檢討結果,所有變動本月29日收市後生效。MSCI全中國指數增加成份股56只,剔除54只,其中新增的標的包括中國飛鶴。里昂曾發研報稱,預期在中國飛鶴多元化的投資組合、強大的執行力及創新能力下將帶動公司增加市場份額。該行上調其今明兩年純利預測6%至7%,目標價升至15.7港元,重申“買入”評級,且視之為必需品消費行業的首選。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.